Skip to main content

LCD L33560: Cardiovascular Nuclear Medicine

LCD L33560, Cardiovascular Nuclear Medicine, is the Local Coverage Determination that Wellpoint Federal applies to claims from 10 states (CT, IL, MA, ME, MN, NH, NY, RI and others), effective 2026-04-01 and first in force 2015-10-01. The policy text runs 1,039 words, and its billing and coding article A56743 lists 207 ICD-10-CM codes that support medical necessity for 22 procedure codes. 1 other contractor version share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 207 covered ICD-10-CM codes: 73 more codes than L33960 (CGS Administrators, LLC, 134 codes, revised 2026-01-29).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wellpoint Federal
States and territories
10
CT IL MA ME MN NH NY RI VT WI
Revision effective
2026-04-01
Original effective
2015-10-01
Policy text
1,039 words
Covered ICD-10 codes (articles)
207

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L33560
ContractContractorTypeStates
06101Wellpoint FederalMAC - Part AIL
06201Wellpoint FederalMAC - Part AMN
06301Wellpoint FederalMAC - Part AWI
06102Wellpoint FederalMAC - Part BIL
06202Wellpoint FederalMAC - Part BMN
06302Wellpoint FederalMAC - Part BWI
13101Wellpoint FederalA and B and HHH MACCT
13201Wellpoint FederalA and B and HHH MACNY
13102Wellpoint FederalA and B and HHH MACCT
13202Wellpoint FederalA and B and HHH MACNY
13282Wellpoint FederalA and B and HHH MACNY
13292Wellpoint FederalA and B and HHH MACNY
14411Wellpoint FederalA and B and HHH MACRI
14211Wellpoint FederalA and B and HHH MACMA
14311Wellpoint FederalA and B and HHH MACNH
14511Wellpoint FederalA and B and HHH MACVT
14111Wellpoint FederalA and B and HHH MACME
14112Wellpoint FederalA and B and HHH MACME
14212Wellpoint FederalA and B and HHH MACMA
14312Wellpoint FederalA and B and HHH MACNH
14512Wellpoint FederalA and B and HHH MACVT
14412Wellpoint FederalA and B and HHH MACRI

Billing and coding article A56743: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56743 (Billing and Coding: Cardiovascular Nuclear Medicine) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A56743: Billing and Coding: Cardiovascular Nuclear Medicine (Billing and Coding, effective 2026-10-01)

Covered ICD-10-CM codes
207
3 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
22
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56743
ICD-10-CMDescription (FY2027)
I20.0Unstable angina
I20.1Angina pectoris with documented spasm
I20.81Angina pectoris with coronary microvascular dysfunction
I20.89Other forms of angina pectoris
I20.9Angina pectoris, unspecified
I21.01ST elevation (STEMI) myocardial infarction involving left main coronary artery
I21.02ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery
I21.09ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
I21.11ST elevation (STEMI) myocardial infarction involving right coronary artery
I21.19ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
I21.21ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery
I21.29ST elevation (STEMI) myocardial infarction involving other sites
I21.3ST elevation (STEMI) myocardial infarction of unspecified site
I21.4Non-ST elevation (NSTEMI) myocardial infarction
I21.9Acute myocardial infarction, unspecified
I21.A1Myocardial infarction type 2
I21.A9Other myocardial infarction type
I21.BMyocardial infarction with coronary microvascular dysfunction
I22.0Subsequent ST elevation (STEMI) myocardial infarction of anterior wall
I22.1Subsequent ST elevation (STEMI) myocardial infarction of inferior wall
I22.2Subsequent non-ST elevation (NSTEMI) myocardial infarction
I22.8Subsequent ST elevation (STEMI) myocardial infarction of other sites
I22.9Subsequent ST elevation (STEMI) myocardial infarction of unspecified site
I23.0Hemopericardium as current complication following acute myocardial infarction

Procedure codes: 78451, 78452, 78453, 78454, 78466, 78468, 78469, 78472, 78473, 78481, 78483, 78494, 78496, A9500 (Technetium tc-99m sestamibi, diagnostic, per study dose), A9501 (Technetium tc-99m teboroxime, diagnostic, per study dose), A9502 (Technetium tc-99m tetrofosmin, diagnostic, per study dose), A9505 (Thallium tl-201 thallous chloride, diagnostic, per millicurie), A9512 (Technetium tc-99m pertechnetate, diagnostic, per millicurie), A9520 (Technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries), A9538 (Technetium tc-99m pyrophosphate, diagnostic, per study dose, up to 25 millicuries), A9560 (Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries), C9176 (Tc-99m from domestically produced non-heu mo-99, [minimum 50 percent], full cost recovery add-on, per study dose).

Coverage indications, limitations and medical necessity

Abstract:

Cardiovascular nuclear imaging employs non-invasive techniques to assess alterations in coronary artery flow, and ventricular function.

The specific imaging technique (perfusion versus ventricular function) and the reason for the imaging determine which radionuclide agent is employed. A myocardial perfusion study utilizes an imaging isotope agent that reflects segmental and global myocardial blood flow and uptake, the interpretation of which is used to make inference about the presence of scar and ischemia.

Ventricular function studies utilize specific imaging isotopes to outline the borders of the ventricular endocardium, or to identify the ventricular blood pool independent of the surrounding myocardium. The motion of the left ventricle, synchronized with the electrocardiogram, is used to generate wall motion and ejection fraction information.

These tests may be performed at rest and during exercise, or with pharmacologic intervention when exercise cannot be performed. The acquisition of the images may be planar (single plane) or by multiple planes with computer integration, SPECT (single-photon emission computer tomography).

Indications:

Cardiovascular nuclear imaging is indicated for the following:

Assessment of the functional and prognostic importance of angina;

Diagnostic evaluation of patients with chest pain and uninterpretable or equivocal ECG changes caused by drugs, bundle branch block, or left ventricular hypertrophy;

Assessment of congenital anomalies of coronary arteries;

Risk assessment or re-evaluation of disease in patients who are asymptomatic or have stable symptoms, with known atherosclerotic heart disease on catheterization or SPECT perfusion imaging, who have not had a revascularization procedure within the past two years;

Detection of coronary artery disease in patients, without chest pain syndrome, with new-onset of diagnosed heart failure or left ventricular systolic dysfunction;

Evaluation of ischemic versus non-ischemic cardiomyopathy when cardiac catheterization / coronary angiography are not planned;

Evaluation of myocardial perfusion and/or function before and after coronary artery bypass surgery or other re-perfusion procedures;

Quantification and surveillance of myocardial infarction and prognostication in patients with infarction;

Preoperative assessment for non-cardiac surgery, when used to determine risk for surgery and/or perioperative management in:

• patients with minor or intermediate clinical risk predictors and poor functional capacity;

• patients with intermediate or high likelihood of coronary heart disease, or

• patients with poor functional capacity undergoing high risk non-cardiac surgery;

The "ACA/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Non-Cardiac Surgery" (JACC 2007; 50:e159-e242) provides this information:

High risk surgery: aortic and peripheral vascular surgery

Intermediate risk surgery: intraperitoneal and intrathoracic surgery, carotid endarterectomy, head & neck surgery, orthopedic surgery, prostate surgery.

Low risk surgery: endoscopic procedures, superficial surgery, cataract surgery, breast surgery, ambulatory surgery

Poor functional capacity = less than 4 METS

Clinical risk factors:

1) history of ischemic heart disease

2) history of compensated or prior heart failure

3) history of cerebrovascular disease

4) diabetes mellitus

5) renal insufficiency

Decision-making for testing is based upon the presence of multiple clinical risk factors, the level of functional capacity, the risk of the surgery and the likelihood that the results of the cardiac testing would change the management.

Evaluation of ventricular function in patients with non-ischemic myocardial disease;

Evaluation of patients in whom an accurate measure of the ejection fraction is needed to make a determination of whether to implant a defibrillator or biventricular pacemaker;

Evaluation of a patient receiving chemotherapeutic drugs which are potentially cardiotoxic (e.g., adriamycin).

First pass studies will be considered medically necessary only when information sought is immediately relevant to the management of the patient’s clinical condition, and has not been previously obtained or likely to be obtained from other planned tests such as echocardiography or equilibrium gated blood pool studies. First pass studies may be indicated for the assessment and identification of shunts.

Infarct avid scintigraphy is indicated in patients in whom it is not possible to make a definitive diagnosis of myocardial infarction by EKG or enzyme testing.

Patient selection should be based on clinical grounds:

Patients with a high pretest probability of disease are not usually candidates for a study for diagnostic purposes, though the size and reversibility of a defect and its functional consequences may be required for clinical decision-making.

Patients with a moderate probability of disease benefit the most from the study when the diagnosis is in question.

Selection of tests should be made within the context of other tests, scheduled and previously performed, so that the anticipated information obtained is unique and not redundant.

Limitations:

Special Equipment Requirements:

Given the limitations of uptake, low photon energy and redistribution, the cardiac blood pool codes and perfusion imaging codes are not generally covered on the same date of service. However, in light of the predictive value of exercise-induced changes in ejection fraction, an exception will be made to allow first pass, single study with exercise along with the appropriate perfusion studies. Providers who bill this service must certify within their records that their laboratories are specially equipped to process such studies.

All cardiovascular nuclear tests and stress tests must be referred by a physician or a qualified non-physician provider.

All stress tests must be performed under the supervision of a physician or qualified non-physician practitioner. The nuclear test components must be performed under the general supervision of a physician.

Myocardial perfusion studies performed based on the presence of risk factors in the absence of cardiac symptoms, cardiac abnormalities on physical examination, or abnormalities on cardiac testing (e.g., electrocardiographic tests, echocardiography, etc) will be considered screening and denied as not covered by Medicare.

Tests that are anticipated to provide information duplicative of another test already performed will be denied as not medically necessary.

Tests performed when the results would not be anticipated to influence medical management decisions will be denied as not medically necessary.

Myocardial perfusion studies performed subsequent to a diagnostic myocardial PET scan will denied as not medically necessary.

Infarct avid scintigraphy will be denied if the diagnosis of myocardial infarction has already been confirmed by enzymes and/or EKG.

Tests performed unrelated to changes in a patient's signs or symptoms, or for immediate pre-operative evaluation will be denied as medically unnecessary.

Tests performed for risk assessment prior to high risk non-cardiac surgery in asymptomatic patients within one year following normal catheterization or non-invasive test will be considered medically unnecessary and denied.

Tests performed for preoperative evaluation in patients undergoing low-risk surgery will be denied.

Summary of evidence (opening)

N/A

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2026-04-01
Last reviewed by the contractor
2023-09-14
MCD version
36
Derived from
L26859

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L33560 cover?

Cardiovascular nuclear imaging employs non-invasive techniques to assess alterations in coronary artery flow, and ventricular function. The full 1,039-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L33560 apply to?

Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L33560?

The companion billing and coding article A56743 lists 207 ICD-10-CM codes in 3 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L33560?

A denial under LCD L33560 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56743's 207 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.